C- REACTIVE PROTEIN LEVELS AMONG COVID-19 POSITIVE CASES PRESENTING IN GULAB DEVI HOSPITAL LAHORE: A DESCRIPTIVE CROSS-SECTIONAL STUDY

Faiza Javaid; Zahra Nazir Hussain; Sana Haseeb Khan; Fatima Saeed

doi:10.59058/jaimc.v20i3.69

Authors

Faiza Javaid
Zahra Nazir Hussain
Sana Haseeb Khan
Fatima Saeed

DOI:

https://doi.org/10.59058/jaimc.v20i3.69

Keywords:

COVID-19, biomarker, C-reactive protein, Severe COVID-19 disease

Abstract

Background & Objectives: Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is a highly infectious virus associated with the development of COVID 19. Lack of valid biomarkers makes it difficult to predict disease severity. C-reactive protein (CRP) is an acute phase inflammatory marker that which may predict COVID-19 infection and its severity. The aim of this study was to describe the CRP levels in COVID- 19 positive cases presenting in Gulab Devi hospital Lahore.

Methods: In this cross sectional study conducted in Gulab Devi Hospital Lahore for six month, 100 COVID- 19 positive cases were selected using convenient sampling technique. About 3 ml of venous blood was drawn for qualitative and semi-quantitative titration analyses to determine CRP concentration in blood. Descriptive analysis was performed using SPSS version-26 to describe the levels of CRP in relation to clinical features and disease severity.

Results: CRP levels were elevated above normal range in 93% COVID-19 positive cases. Patients with severe infection had high levels of CRP (>6mg/L, range: 12-96 mg/L), mildly infected patients had moderate values of CRP and recovering patients of COVID-19 showed lowest value of CRP (<3mg/L ).

Conclusion: The serum CRP level was substantially higher in COVID-19 positive cases in this study. CRP is an inexpensive, rapid test available to physicians for early detection of COVID-19 severity. Determining CRP levels can also help physicians to identify patients at higher risk of mortality and complications.

References

Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7(2):169-77.

Chen C-C, Lee I-K, Liu J-W, Huang S-Y, Wang L. Utility of C-reactive protein levels for early prediction

of dengue severity in adults. BioMed research inter- national. 2015;2015.

Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease prog- ression. Critical reviews in clinical laboratory sciences. 2020;57(6):389-99.

Zimmer C. The Secret Life of a Coronavirus–An oily, 100-nanometer-wide bubble of genes has killed more than two million people and reshaped the world. Scien- tists don't quite know what to make of it. Scientists don't quite know what to make of it Retrieved. 2021; 28.

Mahase E. China coronavirus: mild but infectious cases may make it hard to control outbreak, report warns. British Medical Journal Publishing Group; 2020.

Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences. 2020;63(3):457-60.

Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020; 382(18):1708-20.

Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and serological investigation of 2019- nCoV infected patients: implication of multiple shed- ding routes. Emerging microbes & infections. 2020; 9(1):386-9.

Chalmers S, Khawaja A, Wieruszewski PM, Gajic O, Odeyemi Y. Diagnosis and treatment of acute pulmo- nary inflammation in critically ill patients: the role of inflammatory biomarkers. World journal of critical care medicine. 2019;8(5):59.

Vuong NL, Le Duyen HT, Lam PK, Tam DTH, Vinh Chau NV, Van Kinh N, et al. C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study. BMC medicine. 2020;18(1):1-13.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020; 395 (10223):507-13.

Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune bio- marker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID- 19): a meta-analysis. Clinical Chemistry and Labo- ratory Medicine (CCLM). 2020;58(7):1021-8.

Tillett WS, Francis Jr T. Serological reactions in pneu- monia with a non-protein somatic fraction of pneumo-

coccus. The Journal of experimental medicine. 1930; 52(4):561.

STRAC A. Molecular and serological investigation of 2019-nCoVinfected patients: implication of multiple shedding routes.

Zhou R, To KK-W, Wong Y-C, Liu L, Zhou B, Li X, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020; 53(4): 864-77. e5.

Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. Journal of medical virology. 2020; 92(4): 401.

Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procal- citonin in patients with COVID-19. Journal of clinical virology. 2020;127:104370.

Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C- reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early. Journal of medical virology. 2020;92(7):856-62.